We are proud to announce the addition of Scott Ward to our Board of Directors. Scott is a distinguished healthcare and medical technology leader, bringing decades of experience and a strategic perspective that will help guide Evident as we continue to grow and innovate. His expertise will be invaluable as we navigate this transformative time in our company’s growth and prepare for the exciting milestones ahead. His commitment to improving patient outcomes makes him a perfect fit for our mission. As we advance our next-generation AI-powered IVUS platform, his insights will be instrumental in shaping the future of vascular imaging and intervention. Welcome, Scott, to the Evident Vascular team!
About us
Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.
- Website
-
https://evidentvascular.com
External link for Evident Vascular, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- San Jose, California
- Type
- Privately Held
- Founded
- 2021
- Specialties
- imaging, IVUS, intravascular, peripheral vascular, cardiovascular, PVD, CVD, PCI, image guided therapy , vascular, medtech, medtech startup, endovascular, interventional radiology , vascular surgery, and interventional cardiology
Locations
-
Primary
Get directions
142 Charcot Ave
San Jose, California 95131, US
Employees at Evident Vascular, Inc.
Updates
-
Evident Vascular, Inc. reposted this
📢 ACC 2024 🗞️ Large prospective RCT demonstrates IVUS-guided DCB intervention in fempop 🦵 disease provides significantly improved clinical outcomes! Now if only there was a next generation IVUS platform with better image quality, improved ease of use, and AI-enabled capabilities that clinicians actually wanted to use… Check out —> Evident Vascular, Inc. Cc: Howard Rosen
Director of Vascular Intervention, BIDMC; Section Head, Interventional Cardiology and Vascular Research, Smith Center for Outcomes Research; Associate Professor of Medicine, Harvard Medical School
Second Prospective Randomized Control Trial Demonstrating the Benefit of Peripheral IVUS! 237 patients with fempop disease randomized to IVUS-guided DCB treatment vs angio-guided DCB treatment. 14% improvement in patency at 1 year. Summary of results here: https://lnkd.in/gU-3Vggz This aligns with the 17% patency improvement seen in the Allan et al 150 person fem-pop RCT trail published in 2022: (https://lnkd.in/gRtz-rQr). Time is now to change your peripheral practice!! Learn more about peripheral IVUS here: https://lnkd.in/g-m7EpWg Society for Vascular Medicine Society for Cardiovascular Angiography & Interventions Society of Interventional Radiology VIVA Physicians
Comparison of IVUS-Guided vs. Angiography-Guided Angioplasty for the Outcomes of Drug-Coated Balloon in the Treatment of Femoropopliteal Artery Disease - American College of Cardiology
acc.org
-
Scientific Advisory Board Member Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM is the leading author of a new study published in the Journal of Society for Cardiovascular Angiography & Interventions (SCAI). The report underscores the need to broaden the adoption of intravascular ultrasound (#IVUS) in peripheral arterial and deep venous interventions, emphasizing its crucial role in advancing patient care. Evident Vascular CEO Howard Rosen, Vensana Capital Co-Founder and Managing Partner Justin Klein, MD, JD and Vensana Capital Partner Cynthia Yee shared insights and perspective in a new MedTech Strategist article. Together, they weighed in on the implications of this research and highlighted ongoing efforts to develop an advanced solution that will enable more accurate diagnosis and treatment and provide better clinical outcomes. “Our aim is to significantly enhance adoption rates by streamlining workflow, improving imaging quality for better interpretation, and integrating AI to simplify the process,” Rosen said. “The driving force of Evident Vascular is to address the existing shortcomings and obstacles that are preventing clinicians from utilizing IVUS to its full potential for the benefit of their patients.” #MedicalInnovation #CardiovasularHealth #PVD #CVD #intravascularimaging #imageguidedtherapy #startup #medtech